Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 22, 2010

Karolinska Institutet Awarded $13M to Establish Regenerative Medicine Research Center

  • Sweden’s Karolinska Institutet has received a SEK100 million (about $13 million) grant from the Knut and Alice Wallenberg Foundation to establish a regenerative medicine research center. Work at the new Wallenberg Institute for Regenerative Medicine (WIRM) will cover a broad range of therapeutic fields, with a particular focus on the continued development of bone-marrow transplantation technologies for disorders that currently can’t be treated.

    “The establishment of WIRM represents a unique opportunity to bring Karolinska Institutet’s internationally leading basic research and clinical research together at a completely new center,” comments Urban Lendahl, Ph.D., WIRM scientific director. “It will make it possible to address research issues we currently lack the resources to tackle.”

    Karolinska Institutet claims to be one of few universities with capabilities and expertise in the whole spectrum of regenerative medicine, from experimental stem cell research to clinical applications of cell therapy and regenerative medicine. Establishment of the WIRM will allow the university to bolster its capabilities with new technical equipment and experimental techniques. “The grant opens up fantastic opportunities for us to pursue pioneering research at the very highest international level in these extremely important areas,” states Harriet Wallberg-Henriksson, M.D., president of Karolinska Institutet.



Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Pharmacists and Prescription Drug Misuse Programs

Do you agree that pharmacists should make a greater effort to become more involved with prescription drug-monitoring programs?

More »